213 related articles for article (PubMed ID: 36146620)
1. Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review.
Goodman E; Reuschenbach M; Kaminski A; Ronnebaum S
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146620
[TBL] [Abstract][Full Text] [Related]
2. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
[TBL] [Abstract][Full Text] [Related]
4. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer.
Kamolratanakul S; Pitisuttithum P
Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960159
[TBL] [Abstract][Full Text] [Related]
5. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
Drolet M; Bénard É; Pérez N; Brisson M;
Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus genotype distribution patterns in Zimbabwe; is the bivalent vaccine sufficient?
Marembo T; Fitzpatrick MB; Dube Mandishora RS
Intervirology; 2024 Apr; 67(1):55-63. PubMed ID: 38574482
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.
Markowitz LE; Drolet M; Perez N; Jit M; Brisson M
Vaccine; 2018 Aug; 36(32 Pt A):4806-4815. PubMed ID: 29802000
[TBL] [Abstract][Full Text] [Related]
8. Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources.
Wang W; Kothari S; Baay M; Garland SM; Giuliano AR; Nygård M; Velicer C; Tota J; Sinha A; Skufca J; Verstraeten T; Sundström K
Expert Rev Vaccines; 2022 Feb; 21(2):227-240. PubMed ID: 34845951
[TBL] [Abstract][Full Text] [Related]
9. Summary of the National Advisory Committee on Immunization's updated recommendations on human papillomavirus (HPV) vaccines: Nine-valent human papillomavirus (HPV) of minimum intervals between doses in the HPV immunization schedule.
Tunis MC; Deeks SL;
Can Commun Dis Rep; 2016 Jul; 42(7):149-151. PubMed ID: 29770021
[TBL] [Abstract][Full Text] [Related]
10. HPV vaccination in head and neck HPV-related pathologies.
Wierzbicka M; Józefiak A; Jackowska J; Szydłowski J; Goździcka-Józefiak A
Otolaryngol Pol; 2014; 68(4):157-73. PubMed ID: 24981297
[TBL] [Abstract][Full Text] [Related]
11. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson R; Nugent D; Bennett K; Doré CJ; Murray ML; Meadows J; Haddow LJ; Lacey C; Sandmann F; Jit M; Soldan K; Tetlow M; Caverly E; Nathan M; Copas AJ
Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
[TBL] [Abstract][Full Text] [Related]
12. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
13. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada.
Steben M; Tan Thompson M; Rodier C; Mallette N; Racovitan V; DeAngelis F; Stutz M; Rampakakis E
J Obstet Gynaecol Can; 2018 Dec; 40(12):1635-1645. PubMed ID: 30341021
[TBL] [Abstract][Full Text] [Related]
14. Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial.
Smahelova J; Hamsikova E; Ludvikova V; Vydrova J; Traboulsi J; Vencalek O; Lukeš P; Tachezy R
JAMA Otolaryngol Head Neck Surg; 2022 Jul; 148(7):654-661. PubMed ID: 35653138
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
16. The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: A literature review.
Pham CT; Juhasz M; Sung CT; Mesinkovska NA
J Am Acad Dermatol; 2020 Jan; 82(1):202-212. PubMed ID: 31085272
[TBL] [Abstract][Full Text] [Related]
17. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
Garland SM; Kjaer SK; Muñoz N; Block SL; Brown DR; DiNubile MJ; Lindsay BR; Kuter BJ; Perez G; Dominiak-Felden G; Saah AJ; Drury R; Das R; Velicer C
Clin Infect Dis; 2016 Aug; 63(4):519-27. PubMed ID: 27230391
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016.
Martínez-Gómez X; Curran A; Campins M; Alemany L; Rodrigo-Pendás JÁ; Borruel N; Castellsagué X; Díaz-de-Heredia C; Moraga-Llop FA; Del Pino M; Torné A
Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782268
[TBL] [Abstract][Full Text] [Related]
19. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
[TBL] [Abstract][Full Text] [Related]
20. The incidence, clearance and persistence of non-cervical human papillomavirus infections: a systematic review of the literature.
Taylor S; Bunge E; Bakker M; Castellsagué X
BMC Infect Dis; 2016 Jun; 16():293. PubMed ID: 27301867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
